Tata Aggressive Hybrid Fund Regular-Growth
The fund is rated 2 stars. A strength was asset mix, while balance between returns and downside risk provided some support. Investment selection within each industry was the main limitation and did not provide enough support for a higher rating. Higher annual fee of 2.14% was a minor drawback.
This fund has a good track record with Asset Allocation, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 4069.008 AUM and a 2.14 expense ratio. Considering all these factors, we have rated this fund as 2.0 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
8 Oct 2026 મુજબ
જોખમ ગુણોત્તર
30 Sep 2026 મુજબ
ડેટ મેટ્રિક્સ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (99)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| ICICI Bank Ltd. | 4.65% | ₹189.02 Cr | 13,00,000 |
| Bharti Airtel Ltd. | 3.56% | ₹144.95 Cr | 8,00,000 |
| HDFC Bank Ltd. | 2.96% | ₹120.53 Cr | 17,00,000 |
| GOIકૂપન 6.94% · પરિપક્વતા 11/05/2036 · રેટિંગ SOV | 2.82% | ₹114.87 Cr | 1,14,97,100 |
| Reliance Industries Ltd. | 2.51% | ₹102.16 Cr | 8,00,000 |
| Coforge Ltd. | 2.44% | ₹99.27 Cr | 5,00,000 |
| Axis Bank Ltd. | 2.24% | ₹91 Cr | 7,00,000 |
| Mahindra & Mahindra Ltd. | 2.10% | ₹85.33 Cr | 2,60,000 |
| Britannia Industries Ltd. | 1.88% | ₹76.39 Cr | 1,45,500 |
| Glaxosmithkline Pharmaceuticals Ltd. | 1.87% | ₹76.25 Cr | 2,50,000 |
ફંડ વિગતો
Long Term Capital Appreciation. Investment predominantly in equity & equity related instruments (65% - 80%) & some portion
The scheme seeks to provide income distribution and or capital appreciation over medium to long term.
Exit load of 0.50%, if redeemed within 30 days.